PUBLISHER: Persistence Market Research | PRODUCT CODE: 1457348

PUBLISHER: Persistence Market Research | PRODUCT CODE: 1457348

Hypercalcemia Treatment Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2030

PUBLISHED: February 19, 2024

PAGES: 223 Pages

DELIVERY TIME: 2-5 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Persistence Market Research has recently published an in-depth analysis of the global hypercalcemia treatment market, providing a comprehensive overview of the industry's dynamics, growth drivers, challenges, and emerging trends. This report furnishes valuable insights into the structure of the hypercalcemia treatment market, offering exclusive data and statistics that forecast the market's trajectory from 2023 to 2030.

The global hypercalcemia treatment market is forecast to expand at a CAGR of 11.8% and thereby increase from a value of US$18.3 Mn in 2023, to US$40 Mn by the end of 2030.

Key Insights:

Hypercalcemia Treatment Market Size (2023E): US$18.3 Mn
Projected Market Value (2030F): US$40.0 Mn
Global Market Growth Rate (CAGR 2023 to 2030): 11.8%
Historical Market Growth Rate (CAGR 2018 to 2022): 10.8%

Hypercalcemia Treatment Market - Report Scope:

The hypercalcemia treatment market encompasses a range of pharmaceuticals, therapies, and interventions aimed at managing elevated levels of calcium in the blood. Conditions such as primary hyperparathyroidism, malignancy-related hypercalcemia, and other metabolic disorders necessitate effective treatment strategies to mitigate associated risks and complications. Market growth is primarily driven by the increasing prevalence of hypercalcemia, advancements in treatment modalities, and growing awareness among healthcare professionals and patients.

Market Growth Drivers:

The hypercalcemia treatment market is fueled by the rising incidence of conditions leading to elevated calcium levels, such as hyperparathyroidism, cancer, and renal failure. Technological advancements in diagnostic techniques, including imaging modalities and biochemical assays, facilitate early detection and prompt initiation of treatment, driving market expansion. Additionally, the introduction of novel pharmaceutical agents, including calcimimetics and bisphosphonates, offers more targeted and efficacious treatment options, further augmenting market growth.

Market Restraints:

Despite significant growth prospects, the hypercalcemia treatment market faces challenges associated with limited treatment options for refractory hypercalcemia and adverse effects associated with certain pharmacological interventions. Furthermore, the high cost of novel therapeutics and the stringent regulatory framework governing drug approval pose barriers to market penetration. Additionally, variations in disease etiology and patient response to treatment necessitate personalized approaches, adding complexity to therapeutic decision-making and management strategies.

Market Opportunities:

The hypercalcemia treatment market presents promising opportunities driven by ongoing research and development initiatives focused on identifying novel therapeutic targets and treatment modalities. Advancements in precision medicine, including molecular profiling and targeted therapy, hold potential for more personalized and effective treatment approaches. Moreover, the integration of artificial intelligence and big data analytics in healthcare facilitates data-driven decision-making and enhances treatment outcomes, fostering market growth and differentiation.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the hypercalcemia treatment market?
Which therapeutic modalities are witnessing increased adoption in the management of hypercalcemia?
What are the key challenges and restraints hindering market growth?
Who are the leading players in the hypercalcemia treatment market, and what are their strategic initiatives?
What are the emerging trends and future prospects in the global hypercalcemia treatment market?

Competitive Intelligence and Business Strategy:

Leading pharmaceutical companies, including., dominate the hypercalcemia treatment market through a combination of product innovation, strategic partnerships, and acquisitions. These companies invest significantly in research and development to expand their product portfolios and address unmet medical needs in hypercalcemia management. Collaboration with academic institutions and research organizations facilitates the development of novel therapeutics and treatment algorithms, enhancing market competitiveness and driving long-term growth.

Key Companies Profiled:

Amgen Inc.
Pfizer Inc.
Mylan N. V.
Sunovion
Procter And Gamble
Apotex Corporation
Genentech, Inc.
Novartis AG
Bayer AG
Hoffmann La Roche

Hypercalcemia Treatment Market Research Segmentation:

By Product:

Bisphosphonates

Clodronate

Ibandronate

Pamidronate

Zoledronic Acid

Calcitonin
Glucocorticoids
Denosumab
Calcimimetics

By Distribution Channel:

Hospitals
Clinics
Independent Pharmacy & Drug Stores

By Region:

North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa

Product Code: PMRREP34006

1. Executive Summary

1.1. Global Hypercalcemia Treatment Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
2.3. Product Lifecycle Analysis
2.4. Hypercalcemia Treatment Market: Value Chain
- 2.4.1. List of Raw Material Supplier
- 2.4.2. List of Manufacturers
- 2.4.3. List of Distributors
- 2.4.4. List of Applications
- 2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
- 2.7.1. Global Sectorial Outlook
- 2.7.2. Global GDP Growth Outlook
- 2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Product Landscape

3. Global Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

3.1. Key Highlights
- 3.1.1. Market Volume (Units) Projections
- 3.1.2. Market Size and Y-o-Y Growth
- 3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
- 3.2.1. Historical Market Size Analysis, 2013-2016
- 3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global Hypercalcemia Treatment Market Outlook: Product
- 3.3.1. Introduction / Key Findings
- 3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Product, 2018 - 2022
- 3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
  - 3.3.3.1. Bisphosphonates
    - 3.3.3.1.1. Clodronate
    - 3.3.3.1.2. Ibandronate
    - 3.3.3.1.3. Pamidronate
    - 3.3.3.1.4. Zoledronic Acid
  - 3.3.3.2. Calcitonin
  - 3.3.3.3. Glucocorticoids
  - 3.3.3.4. Denosumab
  - 3.3.3.5. Calcimimetics
3.4. Market Attractiveness Analysis: Product
3.5. Global Hypercalcemia Treatment Market Outlook: Distribution Channel
- 3.5.1. Introduction / Key Findings
- 3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Distribution Channel, 2018 - 2022
- 3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
  - 3.5.3.1. Hospitals
  - 3.5.3.2. Clinics
  - 3.5.3.3. Independent Pharmacy & Drug Stores
3.6. Market Attractiveness Analysis: Distribution Channel

4. Global Hypercalcemia Treatment Market Outlook: Region

4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
- 4.3.1. North America
- 4.3.2. Europe
- 4.3.3. East Asia
- 4.3.4. South Asia and Oceania
- 4.3.5. Latin America
- 4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region

5. North America Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 5.3.1. By Country
- 5.3.2. By Product
- 5.3.3. By Distribution Channel
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 5.4.1. U.S.
- 5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
- 5.5.1. Bisphosphonates
  - 5.5.1.1. Clodronate
  - 5.5.1.2. Ibandronate
  - 5.5.1.3. Pamidronate
  - 5.5.1.4. Zoledronic Acid
- 5.5.2. Calcitonin
- 5.5.3. Glucocorticoids
- 5.5.4. Denosumab
- 5.5.5. Calcimimetics
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
- 5.6.1. Hospitals
- 5.6.2. Clinics
- 5.6.3. Independent Pharmacy & Drug Stores
5.7. Market Attractiveness Analysis

6. Europe Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 6.3.1. By Country
- 6.3.2. By Product
- 6.3.3. By Distribution Channel
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 6.4.1. Germany
- 6.4.2. France
- 6.4.3. U.K.
- 6.4.4. Italy
- 6.4.5. Spain
- 6.4.6. Russia
- 6.4.7. Turkiye
- 6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
- 6.5.1. Bisphosphonates
  - 6.5.1.1. Clodronate
  - 6.5.1.2. Ibandronate
  - 6.5.1.3. Pamidronate
  - 6.5.1.4. Zoledronic Acid
- 6.5.2. Calcitonin
- 6.5.3. Glucocorticoids
- 6.5.4. Denosumab
- 6.5.5. Calcimimetics
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
- 6.6.1. Hospitals
- 6.6.2. Clinics
- 6.6.3. Independent Pharmacy & Drug Stores
6.7. Market Attractiveness Analysis

7. East Asia Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 7.3.1. By Country
- 7.3.2. By Product
- 7.3.3. By Distribution Channel
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 7.4.1. China
- 7.4.2. Japan
- 7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
- 7.5.1. Bisphosphonates
  - 7.5.1.1. Clodronate
  - 7.5.1.2. Ibandronate
  - 7.5.1.3. Pamidronate
  - 7.5.1.4. Zoledronic Acid
- 7.5.2. Calcitonin
- 7.5.3. Glucocorticoids
- 7.5.4. Denosumab
- 7.5.5. Calcimimetics
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
- 7.6.1. Hospitals
- 7.6.2. CLINICS
- 7.6.3. INDEPENDENT PHARMACY & DRUG STORES
7.7. Market Attractiveness Analysis

8. South Asia & Oceania Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 8.3.1. By Country
- 8.3.2. By Product
- 8.3.3. By Distribution Channel
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 8.4.1. India
- 8.4.2. Southeast Asia
- 8.4.3. ANZ
- 8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
- 8.5.1. Bisphosphonates
  - 8.5.1.1. Clodronate
  - 8.5.1.2. Ibandronate
  - 8.5.1.3. Pamidronate
  - 8.5.1.4. Zoledronic Acid
- 8.5.2. Calcitonin
- 8.5.3. Glucocorticoids
- 8.5.4. Denosumab
- 8.5.5. Calcimimetics
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
- 8.6.1. Hospitals
- 8.6.2. CLINICS
- 8.6.3. INDEPENDENT PHARMACY & DRUG STORES
8.7. Market Attractiveness Analysis

9. Latin America Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 9.3.1. By Country
- 9.3.2. By Product
- 9.3.3. By Distribution Channel
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
- 9.5.1. Bisphosphonates
  - 9.5.1.1. Clodronate
  - 9.5.1.2. Ibandronate
  - 9.5.1.3. Pamidronate
  - 9.5.1.4. Zoledronic Acid
- 9.5.2. Calcitonin
- 9.5.3. Glucocorticoids
- 9.5.4. Denosumab
- 9.5.5. Calcimimetics
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
- 9.6.1. Hospitals
- 9.6.2. CLINICS
- 9.6.3. INDEPENDENT PHARMACY & DRUG STORES
9.7. Market Attractiveness Analysis

10. Middle East & Africa Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 10.3.1. By Country
- 10.3.2. By Product
- 10.3.3. By Distribution Channel
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 10.4.1. GCC
- 10.4.2. Egypt
- 10.4.3. South Africa
- 10.4.4. Northern Africa
- 10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
- 10.5.1. Bisphosphonates
  - 10.5.1.1. Clodronate
  - 10.5.1.2. Ibandronate
  - 10.5.1.3. Pamidronate
  - 10.5.1.4. Zoledronic Acid
- 10.5.2. Calcitonin
- 10.5.3. Glucocorticoids
- 10.5.4. Denosumab
- 10.5.5. Calcimimetics
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
- 10.6.1. Hospitals
- 10.6.2. CLINICS
- 10.6.3. INDEPENDENT PHARMACY & DRUG STORES
10.7. Market Attractiveness Analysis

11. Competition Landscape

11.1. Market Share Analysis, 2022
11.2. Market Structure
- 11.2.1. Competition Intensity Mapping By Market
- 11.2.2. Competition Dashboard
- 11.2.3. Apparent Product Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 11.3.1. Amgen Inc.
  - 11.3.1.1. Overview
  - 11.3.1.2. Segments and Product
  - 11.3.1.3. Key Financials
  - 11.3.1.4. Market Developments
  - 11.3.1.5. Market Strategy
- 11.3.2. Pfizer Inc.
  - 11.3.2.1. Overview
  - 11.3.2.2. Segments and Product
  - 11.3.2.3. Key Financials
  - 11.3.2.4. Market Developments
  - 11.3.2.5. Market Strategy
- 11.3.3. Mylan N. V.
  - 11.3.3.1. Overview
  - 11.3.3.2. Segments and Product
  - 11.3.3.3. Key Financials
  - 11.3.3.4. Market Developments
  - 11.3.3.5. Market Strategy
- 11.3.4. Sunovion
  - 11.3.4.1. Overview
  - 11.3.4.2. Segments and Product
  - 11.3.4.3. Key Financials
  - 11.3.4.4. Market Developments
  - 11.3.4.5. Market Strategy
- 11.3.5. Procter And Gamble
  - 11.3.5.1. Overview
  - 11.3.5.2. Segments and Product
  - 11.3.5.3. Key Financials
  - 11.3.5.4. Market Developments
  - 11.3.5.5. Market Strategy
- 11.3.6. Apotex Corporation
  - 11.3.6.1. Overview
  - 11.3.6.2. Segments and Product
  - 11.3.6.3. Key Financials
  - 11.3.6.4. Market Developments
  - 11.3.6.5. Market Strategy
- 11.3.7. Genentech, Inc.
  - 11.3.7.1. Overview
  - 11.3.7.2. Segments and Product
  - 11.3.7.3. Key Financials
  - 11.3.7.4. Market Developments
  - 11.3.7.5. Market Strategy
- 11.3.8. Novartis AG
  - 11.3.8.1. Overview
  - 11.3.8.2. Segments and Product
  - 11.3.8.3. Key Financials
  - 11.3.8.4. Market Developments
  - 11.3.8.5. Market Strategy
- 11.3.9. Bayer AG
  - 11.3.9.1. Overview
  - 11.3.9.2. Segments and Product
  - 11.3.9.3. Key Financials
  - 11.3.9.4. Market Developments
  - 11.3.9.5. Market Strategy
- 11.3.10. Hoffmann La Roche
  - 11.3.10.1. Overview
  - 11.3.10.2. Segments and Product
  - 11.3.10.3. Key Financials
  - 11.3.10.4. Market Developments
  - 11.3.10.5. Market Strategy
- 11.3.11. Atnahs Pharma
  - 11.3.11.1. Overview
  - 11.3.11.2. Segments and Product
  - 11.3.11.3. Key Financials
  - 11.3.11.4. Market Developments
  - 11.3.11.5. Market Strategy
- 11.3.12. Cipla Inc.
  - 11.3.12.1. Overview
  - 11.3.12.2. Segments and Product
  - 11.3.12.3. Key Financials
  - 11.3.12.4. Market Developments
  - 11.3.12.5. Market Strategy
- 11.3.13. Sun Pharmaceuticals Industries Ltd
  - 11.3.13.1. Overview
  - 11.3.13.2. Segments and Product
  - 11.3.13.3. Key Financials
  - 11.3.13.4. Market Developments
  - 11.3.13.5. Market Strategy
- 11.3.14. Dr. Reddy's Laboratories
  - 11.3.14.1. Overview
  - 11.3.14.2. Segments and Product
  - 11.3.14.3. Key Financials
  - 11.3.14.4. Market Developments
  - 11.3.14.5. Market Strategy
- 11.3.15. Aurobindo Pharma Limited
  - 11.3.15.1. Overview
  - 11.3.15.2. Segments and Product
  - 11.3.15.3. Key Financials
  - 11.3.15.4. Market Developments
  - 11.3.15.5. Market Strategy

12. Appendix

12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ